SCHEMBL5453329

SCHEMBL5453329

Fc1ccc(-c2nn3c(NC4CCCC4)cccc3c2-c2cc(-c3ccccc3)nc(NC3CCCC3)n2)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.47
MAPK14 Q16539 2/20 0.41
MAPT P10636 2/20 0.40
RAB9A P51151 2/20 0.40
TP53 P04637 1/20 0.40
RXFP1 Q9HBX9 1/20 0.40
VCP P55072 1/20 0.39
ALOX5 P09917 1/20 0.39
MEN1 O00255 1/20 0.39
ALDH1A1 P00352 1/20 0.39
LMNA P02545 1/20 0.39
GLA P06280 1/20 0.39
POLB P06746 1/20 0.39
GAA P10253 1/20 0.39
KMT2A Q03164 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
CDC7 O00311 1/20 0.39
DBF4 Q9UBU7 1/20 0.39
GSK3B P49841 1/20 0.38
ADORA1 P30542 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5455132 0.91 MAPK14 (0.48) KDM4EMAPK14MAPTTP53RXFP1
SCHEMBL14339923 0.91 KDM4E (0.41) KDM4EMAPK14MAPTTP53RXFP1
SCHEMBL5457242 0.89 PTGS2 (0.45) KDM4EMAPK14RAB9AALOX5MEN1
SCHEMBL5457257 0.86 MAPK14 (0.40) KDM4EMAPK14MAPTTP53RXFP1
SCHEMBL5457541 0.86 KDM4E (0.42) KDM4EMAPK14MAPTTP53RXFP1
SCHEMBL6490784 0.86 KDM4E (0.48) KDM4EMAPK14VCPALOX5CDC7
SCHEMBL5456838 0.86 CSNK1D (0.51) MAPK14GSK3BCSNK1DCDK4
SCHEMBL5457552 0.85 KDM4E (0.51) KDM4EMAPK14MAPTTP53RXFP1
SCHEMBL5462491 0.85 CSNK1D (0.51) MAPK14GSK3BCSNK1DCDK4
Hydrochloric Acid SCHEMBL5454770 0.85 KDM4E (0.50) KDM4EMAPK14MAPTTP53RXFP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1377573-B1 PYRAZOLOPYRIDINE DERIVATIVES GLAXO GROUP LTD (GB) 2005-07-27 EP claimed
US-20070287721-A1 Pyrazolopyridinyl pyridine BOYD F LESLIE 2007-12-13 US disclosed
US-20070287721-A1 Pyrazolopyridinyl pyridine BOYD F LESLIE 2007-12-13 US disclosed
US-20070287721-A1 Pyrazolopyridinyl pyridine BOYD F LESLIE 2007-12-13 US disclosed
US-7163940-B2 Pyrazolopyridinyl pyrimidine therapeutic compounds SMITHKLINE BEECHAM CORPORATION (US) 2007-01-16 US disclosed
US-7163940-B2 Pyrazolopyridinyl pyrimidine therapeutic compounds SMITHKLINE BEECHAM CORPORATION (US) 2007-01-16 US disclosed
EP-1377573-B1 PYRAZOLOPYRIDINE DERIVATIVES GLAXO GROUP LTD (GB) 2005-07-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070287721-A1 Pyrazolopyridinyl pyridine CYP3A5, CYP2C19, CYP3A4 KDM4E 1789/4885MAPK14 2533/4885MAPT 1659/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.